Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin for Prevention of Aortic Valve Disease (EAVaLL)
NCT02109614Phase 1Withdrawn
- Start
- May 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of niacin in aortic stenosis (AS), aortic sclerosis and Hyperlipoproteinemia a. Primary endpoint: Calcium score progression by cardiac CT at 2 years. Planned start May 2014; status: withdrawn.
02
Drugs
niacin
03
Conditions
aortic stenosis (AS)aortic sclerosisHyperlipoproteinemia a
Beyond the preview
Go deeper on NCT02109614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109614.